NO20034453D0 - Anvendelse av CD25-bindende molekyler i steroid-resistente pasienter - Google Patents
Anvendelse av CD25-bindende molekyler i steroid-resistente pasienterInfo
- Publication number
- NO20034453D0 NO20034453D0 NO20034453A NO20034453A NO20034453D0 NO 20034453 D0 NO20034453 D0 NO 20034453D0 NO 20034453 A NO20034453 A NO 20034453A NO 20034453 A NO20034453 A NO 20034453A NO 20034453 D0 NO20034453 D0 NO 20034453D0
- Authority
- NO
- Norway
- Prior art keywords
- steroid
- binding molecules
- resistant patients
- resistant
- patient
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0108816A GB0108816D0 (en) | 2001-04-06 | 2001-04-06 | Therapy |
GB0108821A GB0108821D0 (en) | 2001-04-06 | 2001-04-06 | Therapy |
GB0108817A GB0108817D0 (en) | 2001-04-06 | 2001-04-06 | Therapy |
PCT/EP2002/003808 WO2002081508A2 (en) | 2001-04-06 | 2002-04-05 | Use of cd25 binding molecules in steroid-resistant patients |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20034453D0 true NO20034453D0 (no) | 2003-10-03 |
NO20034453L NO20034453L (no) | 2003-12-04 |
Family
ID=27256143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20034453A NO20034453L (no) | 2001-04-06 | 2003-10-03 | Anvendelse av CD25-bindende molekyler i steroid-resistente pasienter |
Country Status (21)
Country | Link |
---|---|
US (2) | US20040146508A1 (no) |
EP (2) | EP2058332A1 (no) |
JP (2) | JP2005502593A (no) |
KR (2) | KR20080110687A (no) |
CN (1) | CN1296386C (no) |
AT (1) | ATE408629T1 (no) |
AU (1) | AU2002315271B2 (no) |
BR (1) | BR0208656A (no) |
CA (1) | CA2443405A1 (no) |
CZ (1) | CZ20032672A3 (no) |
DE (1) | DE60228945D1 (no) |
ES (1) | ES2314067T3 (no) |
HU (1) | HUP0400986A3 (no) |
IL (2) | IL158060A0 (no) |
MX (1) | MXPA03009115A (no) |
NO (1) | NO20034453L (no) |
NZ (1) | NZ528411A (no) |
PL (1) | PL363029A1 (no) |
PT (1) | PT1379557E (no) |
SK (1) | SK12212003A3 (no) |
WO (1) | WO2002081508A2 (no) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005535636A (ja) * | 2002-06-28 | 2005-11-24 | アメリカ合衆国 | インターフェロンβおよびIL−2Rアンタゴニストを用いて自己免疫疾患を治療する方法 |
BRPI0414688A (pt) * | 2003-09-23 | 2006-11-28 | Pdl Biopharma Inc | tratamento de doença respiratória com anti-receptor de il-2 |
GB0507696D0 (en) * | 2005-04-15 | 2005-05-25 | Novartis Ag | Organic compounds |
ES2563955T3 (es) * | 2005-08-02 | 2016-03-16 | Centenary Institute Of Cancer Medicine & Cell Biology | Método para identificar linfocitos T reguladores |
WO2009145831A1 (en) * | 2008-04-02 | 2009-12-03 | Geisinger Clinic | Treatment of the idiopathic nephrotic syndrome spectrum diseases using basiliximab |
JPWO2018159808A1 (ja) * | 2017-03-03 | 2019-12-26 | 国立研究開発法人国立がん研究センター | 抗il−7r抗体の抗体薬物コンジュゲートと、がんまたは炎症を処置することに用いるための、抗il−7r抗体と細胞傷害剤との抗体薬物コンジュゲートを含む医薬組成物 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2188941B (en) * | 1986-04-14 | 1990-06-06 | Bayer Ag | Monoclonal antibodies recognizing human interleukin-2-receptor |
IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
HUT60768A (en) * | 1990-03-16 | 1992-10-28 | Sandoz Ag | Process for producing cd25 fixing molecules |
EP0631783A1 (en) * | 1993-06-03 | 1995-01-04 | Mitsubishi Chemical Corporation | Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives |
US5567590A (en) * | 1994-01-06 | 1996-10-22 | National Jewish Center For Immunology And Respiratory | Methods of diagnosing steroid-resistant inflammation due to type I or type II nuclear glucocorticoid receptor binding abnormalities |
US6013256A (en) * | 1996-09-24 | 2000-01-11 | Protein Design Labs, Inc. | Method of preventing acute rejection following solid organ transplantation |
DK1100829T3 (da) * | 1998-07-27 | 2007-12-27 | Novartis Ag | Anvendelse af basiliximab til behandling af rheumatoid arthritis eller hudsygdomme |
WO2000025816A1 (en) * | 1998-10-30 | 2000-05-11 | The University Of Miami | Treatment of hepatitis c by administration of anti-il-2 receptor monoclonal antibody and an antiviral compound |
GB0007911D0 (en) * | 2000-03-30 | 2000-05-17 | Novartis Ag | Organic compounds |
-
2002
- 2002-04-05 HU HU0400986A patent/HUP0400986A3/hu unknown
- 2002-04-05 JP JP2002579494A patent/JP2005502593A/ja not_active Withdrawn
- 2002-04-05 IL IL15806002A patent/IL158060A0/xx unknown
- 2002-04-05 PT PT02740446T patent/PT1379557E/pt unknown
- 2002-04-05 CZ CZ20032672A patent/CZ20032672A3/cs unknown
- 2002-04-05 AT AT02740446T patent/ATE408629T1/de active
- 2002-04-05 WO PCT/EP2002/003808 patent/WO2002081508A2/en active Application Filing
- 2002-04-05 ES ES02740446T patent/ES2314067T3/es not_active Expired - Lifetime
- 2002-04-05 NZ NZ528411A patent/NZ528411A/en not_active IP Right Cessation
- 2002-04-05 DE DE60228945T patent/DE60228945D1/de not_active Expired - Lifetime
- 2002-04-05 EP EP08016235A patent/EP2058332A1/en not_active Withdrawn
- 2002-04-05 BR BR0208656-5A patent/BR0208656A/pt not_active Application Discontinuation
- 2002-04-05 EP EP02740446A patent/EP1379557B1/en not_active Expired - Lifetime
- 2002-04-05 SK SK1221-2003A patent/SK12212003A3/sk unknown
- 2002-04-05 KR KR1020087028908A patent/KR20080110687A/ko not_active Application Discontinuation
- 2002-04-05 CA CA002443405A patent/CA2443405A1/en not_active Abandoned
- 2002-04-05 KR KR1020037012923A patent/KR100975042B1/ko not_active IP Right Cessation
- 2002-04-05 MX MXPA03009115A patent/MXPA03009115A/es active IP Right Grant
- 2002-04-05 PL PL02363029A patent/PL363029A1/xx not_active Application Discontinuation
- 2002-04-05 CN CNB028074807A patent/CN1296386C/zh not_active Expired - Fee Related
- 2002-04-05 US US10/474,071 patent/US20040146508A1/en not_active Abandoned
- 2002-04-05 AU AU2002315271A patent/AU2002315271B2/en not_active Ceased
-
2003
- 2003-09-22 IL IL158060A patent/IL158060A/en not_active IP Right Cessation
- 2003-10-03 NO NO20034453A patent/NO20034453L/no not_active Application Discontinuation
-
2008
- 2008-12-24 JP JP2008328042A patent/JP2009102367A/ja active Pending
-
2009
- 2009-02-13 US US12/378,454 patent/US20090274691A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN1527840A (zh) | 2004-09-08 |
PT1379557E (pt) | 2008-12-29 |
AU2002315271B2 (en) | 2006-08-03 |
EP2058332A1 (en) | 2009-05-13 |
IL158060A (en) | 2009-12-24 |
EP1379557B1 (en) | 2008-09-17 |
JP2009102367A (ja) | 2009-05-14 |
DE60228945D1 (de) | 2008-10-30 |
CZ20032672A3 (cs) | 2003-12-17 |
PL363029A1 (en) | 2004-11-15 |
IL158060A0 (en) | 2004-03-28 |
MXPA03009115A (es) | 2004-11-22 |
EP1379557A2 (en) | 2004-01-14 |
SK12212003A3 (sk) | 2004-05-04 |
ES2314067T3 (es) | 2009-03-16 |
NZ528411A (en) | 2005-04-29 |
CA2443405A1 (en) | 2002-10-17 |
WO2002081508A2 (en) | 2002-10-17 |
US20040146508A1 (en) | 2004-07-29 |
BR0208656A (pt) | 2004-08-10 |
ATE408629T1 (de) | 2008-10-15 |
HUP0400986A3 (en) | 2012-09-28 |
US20090274691A1 (en) | 2009-11-05 |
JP2005502593A (ja) | 2005-01-27 |
HUP0400986A2 (hu) | 2004-08-30 |
NO20034453L (no) | 2003-12-04 |
CN1296386C (zh) | 2007-01-24 |
KR100975042B1 (ko) | 2010-08-11 |
KR20080110687A (ko) | 2008-12-18 |
WO2002081508A3 (en) | 2003-08-28 |
KR20030088485A (ko) | 2003-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR13C0021I2 (fr) | Conjugates d'exendin-4 et leur utilisation medicale | |
LV12558A (lv) | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate | |
CY1111359T1 (el) | Μεμαντινη για την θεραπεια ηπιας εως μετριας ασθενειας alzheimer | |
TW264480B (no) | ||
ATE510562T1 (de) | Anti-ailim antikörper zur behandlung von crohn's | |
WO2003047524A3 (en) | Methods and compositions for modulating the immune system and uses thereof | |
ATE497775T1 (de) | Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv) | |
TW200630089A (en) | Treatment methods | |
EP1362127A4 (en) | SERPIN-BASED MEDICINAL PRODUCTS FOR THE TREATMENT OF HIV INFECTION AND THE USE THEREOF | |
DE69400799D1 (de) | Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen | |
UA99094C2 (ru) | Способ лечения пациента с системной красной волчанкой | |
DE60231131D1 (de) | Vakzine und verwendung davon zur behandlung amyotrophischer lateralsklerose | |
NO20081149L (no) | Fremgangsmate for behandling av B-celle-maligniteter ved bruk av TACI-IG fusjonsmolekyl | |
KR950700079A (ko) | 이식체-대-숙주 질환을 억제하기 위한 인터루킨-10의 용도(Use of interleukin-10 to suppress graft-vs. -host disease) | |
SE0102147D0 (sv) | New methods | |
NO20034453D0 (no) | Anvendelse av CD25-bindende molekyler i steroid-resistente pasienter | |
BR9912609A (pt) | Métodos de uso de um análogo de somatostatina | |
PT1237562E (pt) | Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas | |
MY124071A (en) | Treatment of viral disease in swine | |
WO2003097082A3 (en) | Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies | |
WO2000063386A3 (en) | Prevention, diagnosis and treatment of lyme disease | |
WO2000078800A3 (en) | Combined decorin binding protein and outer surface protein compositions and methods of use | |
TW200501958A (en) | A therapeutic agent for treating a behavioral disorder | |
UA29106A (uk) | Спосіб лікування вібраційної хвороби | |
PT1150981E (pt) | Composto nucleosidico terapeutico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |